Introduction {#s1}
============

Extended night or rotating shift work is associated with an elevated risk for developing cancer, cardiovascular disease, immune deficiency, mood disorders, and metabolic alterations ([@bib38]; [@bib23]). One major factor believed to contribute to this adverse health impact of shift work is a disruption of endogenous circadian clocks by mistimed resetting stimuli, so called *Zeitgebers*, as a consequence of altered sleep/wake schedules. Most organisms have evolved internal timekeepers to anticipate the environmental changes brought about by the Earth\'s rotation around its axis. In mammals, these so called circadian clocks are based on ubiquitously expressed cellular interlocking transcriptional--translational feedback loops (TTLs) of clock genes/proteins ([@bib3]). In the core TTL, the transcriptional activators circadian locomotor output cycles kaput (CLOCK) and brain and muscle ARNT-like 1 (BMAL1; ARNTL) regulate the expression of two *Cryptochrome* (*Cry1/2*) and three *Period* (*Per1-3*) genes. Towards the end of the day, PER and CRY proteins translocate into the nucleus where they inhibit their own abundance via inhibition of CLOCK/BMAL1. Further accessory loops serve to stabilize this 24-hr feedback rhythm and integrate the clock with cellular processes ([@bib46]). The clock machinery regulates physiology via orchestration of tissue-specific rhythmic expression of clock output genes ([@bib52]).

The external light--dark cycle is the most prominent *Zeitgeber* of the central circadian pacemaker located in the suprachiasmatic nucleus (SCN) of the hypothalamus ([@bib19]). The SCN receives light information from the retina and synchronizes peripheral clocks throughout the body via neuronal and hormonal pathways ([@bib15]). While the SCN itself is largely non-responsive to non-photic timing signals such as food intake, meal timing is an important *Zeitgeber* for clocks in peripheral tissues ([@bib43]). If food access is restricted to the normal rest phase of an organism, that is, the night for humans or daytime for nocturnal rodents, peripheral clocks become uncoupled from the SCN and adapt to the timing of food availability ([@bib14]). Shift workers often eat at times when their digestive timing system is poorly prepared for food ([@bib30]). Animal studies suggest that food intake during the normal rest phase promotes obesity ([@bib5]; [@bib22]) and peripheral circadian uncoupling has been suggested to contribute to the development of metabolic disorders in night shift workers ([@bib4]; [@bib9]). Various other factors can regulate clock gene expression in peripheral tissues, including glucocorticoids and changes in body temperature or autonomic signaling ([@bib15]). The mechanisms of food-dependent peripheral clock resetting, however, remain poorly understood. Metabolic hormones such as insulin, ghrelin, and glucagon (GCG) have been shown to affect circadian rhythms associated with food restriction ([@bib29]; [@bib45]; [@bib12]; [@bib44]). While ghrelin appears to act primarily on the brain, insulin and GCG levels are mainly regulated via blood glucose. However, it was shown that carbohydrate intake alone has only a minor phase resetting capacity, while complex foods show much stronger effects ([@bib24]), indicating that other factors must be involved. Besides the pancreas, other organs---notably including the gastrointestinal tract itself---show acute hormonal responses to fasting or feeding ([@bib42]). This led us to hypothesize that postprandial, gut-derived signals may be implicated in food-driven resetting of peripheral clocks. In a screen using rhythmic liver slice cultures, we identified oxyntomodulin (OXM) as a potent resetting signal of liver circadian clocks. OXM is an anorexigenic incretin hormone produced in the gut by prohormone convertase 1/3-driven cleavage of the precursor preproglucagon (for review see [@bib16]). It modulates energy and glucose metabolism by acting on various tissues, including brain, liver, and pancreas ([@bib6]; [@bib21]). Since OXM secretion is dependent on food intake, we hypothesized that OXM may directly link food intake to hepatic transcriptional activity by resetting of the liver clock.

Results {#s2}
=======

OXM resets the circadian clock in organotypic liver slice cultures {#s2-1}
------------------------------------------------------------------

We screened a commercially available metabolic peptide library (Obesity Peptide Library, Phoenix Europe GmbH; DE) for factors capable of resetting luciferase activity rhythms in organotypic liver slice cultures from *Per2::LUC* circadian reporter mice ([@bib53]). Interestingly, out of 200 peptides applied during the descending phase (∼180°, corresponding to the early morning) of the luciferase activity rhythm, only a few produced marked phase shifts, including three proglucagon-derived peptide (PGDP) hormones: exendin-4, OXM, and GCG ([Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}). Exendin-4 has been isolated from the salivary gland of the *Gila* monster, with no analogue in rodents or humans. To compare the effectiveness of mammalian PGDPs in liver clock resetting, we treated slices with increasing doses of OXM, GCG, and the three other commercially available PGDPs, glicentin-related pancreatic polypeptide (GRPP), glucagon-like peptide-1 (GLP-1), and glucagon-like peptide-2 (GLP-2) ([Figure 1A](#fig1){ref-type="fig"}). GLP-1, GLP-2, and GRPP (0.5--450 nM) had no significant resetting effects on PER2::LUC phase compared to PBS-treatment ([Figure 1B--D](#fig1){ref-type="fig"}). GCG resulted in phase delays of up to 3 hr, but only at relatively high concentrations ([Figure 1E](#fig1){ref-type="fig"}). In contrast, OXM reset PER2::LUC rhythms in liver slices at much lower doses, resulting in phase delays of up to 8 hr at higher concentrations ([Figure 1F](#fig1){ref-type="fig"}). To act as a true *Zeitgeber* signal one would expect differential OXM effects depending on treatment time, that is, a circadian *gating* effect. We tested this by applying OXM at different phases of the PER2::LUC rhythm. To validate the setup, slices were treated at different PER2::LUC phases with 100 μM of the glucocorticoid analog dexamethasone (DEX), which was previously shown to reset hepatocyte clocks in vivo ([@bib8]). In a phase-dependent manner DEX treatment reset PER2::LUC activity rhythms in slices ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Very similar to what had been observed after DEX treatment in animals ([@bib8]), application in the first quarter of the PER2::LUC activity rhythm (0--90°) resulted in phase delays, while later treatments produced phase advances (100--180°) or had no marked effect (around 270°). Likewise, OXM effects were phase dependent. Delays were predominantly observed at 90--210° of the PER2::LUC cycle with a maximum around 180°, while only modest phase shifts were seen at 270--360° ([Figure 1G](#fig1){ref-type="fig"}). Though GCG also showed potential in resetting liver clock rhythms, OXM emerged as the most potent liver clock synchronizer from our screen. Moreover, contrary to GCG, OXM secretion is directly induced by food consumption in humans ([@bib28]), making it an attractive candidate for linking meal timing and clock function. Therefore, we focused on OXM for further analyses.10.7554/eLife.06253.003Figure 1.Oxyntomodulin (OXM) phase- and dose-dependently resets circadian clocks in liver slices.(**A**) Schematic sequence of the proglucagon-derived peptides (GRPP---glicentin-related pancreatic peptide; GLIC---glicentin; OXM---oxyntomodulin; GCG---glucagon; IP-1---intervening peptide-1; GLP-1---glucagon-like peptide-1; IP-2---intervening peptide-2; GLP-2---glucagon-like peptide-2). (**B**--**F**) Example luminescence traces and dose-dependent responses for GLP-1 (**B**; F(6, 28) = 1.509), GLP-2 (**C**; F(6, 28) = 1.530), GRPP (**D**; F(6, 28) = 1.151), GCG (**E**; F(6, 28) = 3.569), and OXM (**F**; F(6, 28) = 8.790)-induced phase resetting of PER2::LUC rhythms in liver slices treated at 180--200°. Data are presented as mean ± S.E.M. (n = 5). One-way ANOVA (F-values with degrees of freedom provided in brackets): \*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001. Asterisks indicate significant differences relative to PBS treatment (white bars). (**G**) Phase response curve for OXM-induced phase resetting of PER2::LUC rhythms in liver slices. Circles: raw data of individual slices; dashed line: sine wave regression with harmonics.**DOI:** [http://dx.doi.org/10.7554/eLife.06253.003](10.7554/eLife.06253.003)10.7554/eLife.06253.004Figure 1---source data 1.Table of effects of metabolic peptide treatment on PER2::LUC liver slice rhythms.**DOI:** [http://dx.doi.org/10.7554/eLife.06253.004](10.7554/eLife.06253.004)10.7554/eLife.06253.005Figure 1---figure supplement 1.Phase response curve for dexamethasone (DEX) treatment in *Per2::LUC* liver slice cultures.Black dots: phase shifts of individual DEX treatments (100 µM); dashed line: sine wave regression with first and second order harmonics (CircWave).**DOI:** [http://dx.doi.org/10.7554/eLife.06253.005](10.7554/eLife.06253.005)

OXM signals via the GCG receptor to activate *Per* gene expression in liver slices {#s2-2}
----------------------------------------------------------------------------------

So far no OXM-specific receptor has been identified; however, OXM can bind to and activate both GCG and GLP-1 receptors ([@bib25]). *Gcgr* transcripts are strongly expressed in the murine liver ([@bib41]). In contrast, the majority of previous studies failed to detect a full-length *Glp1r* mRNA in murine hepatocytes ([@bib11]; [@bib18]; [@bib36]). We performed RT-PCR analyses for all annotated coding *Glp1r* exons on cDNA preparations from wild-type mouse livers with pancreas as positive control. *Glp1r* transcripts were present in pancreas, but undetectable in liver samples ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}), in line with the absence of significant liver clock resetting effects of GLP-1 ([Figure 1B](#fig1){ref-type="fig"}) and potent resetting of PER2::LUC rhythms by OXM treatment in slices from *PER2::LUC x Glp1r*^*−/−*^ mice ([Figure 2A](#fig2){ref-type="fig"}). On the other hand, blocking glucagon receptors (GCGR) signaling by co-treatment with 2-(4-Pyridyl)-5-(4-chlorophenyl)-3-(5-bromo-2-propyloxyphenyl)pyrrol (Calbiochem Glucagon Receptor Inhibitor II; GRI-2) potently inhibited GCG- and OXM-induced clock resetting in *Per2::LUC* slices ([Figure 2B](#fig2){ref-type="fig"}).10.7554/eLife.06253.006Figure 2.Glucagon (GCG) receptor regulates phase resetting effects of OXM and GCG in *Per2::LUC* liver slices.(**A**) OXM-induced phase shifts in *Per2::LUC* and *Per2::LUC* x *Glp1r*^*−/−*^ liver slices. Mann--Whitney test: \#\#p \< 0.01 against solvent. (**B**) GCG and OXM-induced phase shifts in *Per2::LUC* slices are abolished by co-treatment with GRI-2. One-way ANOVA with Bonferroni post-test: p \< 0.05; \#\#\#p \< 0.001 against solvent; \*p \< 0.05; \*\*\*p \< 0.001. Data are presented as mean ± S.E.M. (n = 8); F(7, 56) = 7.314. (**C**) OXM treatment promotes binding of CREB to CRE elements at the *Per1* gene promoter. One-way ANOVA with Bonferroni post-test: \*\*\*p \< 0.001 against 0′. Data are presented as mean ± S.E.M. (n = 5; F(5, 24) = 22.2).**DOI:** [http://dx.doi.org/10.7554/eLife.06253.006](10.7554/eLife.06253.006)10.7554/eLife.06253.007Figure 2---figure supplement 1.Absence of *Glp1r* transcripts in mouse liver.RT-PCR with different primer sets targeting all annotated coding exons of the murine *Glp1r* gene. Exon 1 was not tested, as it mainly contains non-coding poly-C- and poly-G-rich sequences, which precludes specific primer design. cDNA preparations from wild-type livers were tested (lane 2). Wild-type pancreas cDNA was chosen as positive (lane 4) and liver cDNA from *Glp1r*-deficient mice and water as negative controls (lanes 3 and 5). Lane 1: 100-bp DNA ladder.**DOI:** [http://dx.doi.org/10.7554/eLife.06253.007](10.7554/eLife.06253.007)

GCGR is a G protein-coupled receptor that, via protein kinase A, leads to phosphorylation and activation of the transcription factor cyclic adenosine monophosphate (cAMP) response element-binding protein (CREB) ([@bib20]; [@bib13]). This pathway is reminiscent of the SCN, where nocturnal light exposure induces *Per* gene transcription via cAMP signaling and CREB activation downstream of the N-methyl-D-aspartate receptor ([@bib49]). To investigate if OXM would impinge on the hepatic clock machinery in a similar way, we treated liver explants with OXM and performed chromatin immunoprecipitation (ChIP) analysis to measure CREB binding to cAMP response elements (*CRE*) in the *Per1* gene promoter. 30 min after OXM treatment, CREB binding was significantly increased at the *Per1* CRE, but not at downstream sequences ([Figure 2C](#fig2){ref-type="fig"}). In addition, we analyzed clock gene expression in liver slices at different intervals after treatment with OXM at 180°. *Per1* expression was transiently induced 60 min after addition of OXM to the medium, returning back to normal levels after 120 min ([Figure 3A](#fig3){ref-type="fig"}). Similarly, *Per2* was induced by OXM after 60 min, but mRNA levels remained high even after 120 min ([Figure 3B](#fig3){ref-type="fig"}). No significant effect was seen on *Bmal1* expression at all time points ([Figure 3C](#fig3){ref-type="fig"}). In line with the absence of OXM-induced phase shifts at 360° ([Figure 1G](#fig1){ref-type="fig"}), *Per1/2* and *Bmal1* mRNA levels were unaffected by OXM treatment at this phase ([Figure 3D--F](#fig3){ref-type="fig"}). Induction of *Per1* and *Per2* expression was preserved in *Glp1r*^*−/−*^ slices, suggesting that hepatic OXM effects are independent of GLP-1R signaling ([Figure 3G,H](#fig3){ref-type="fig"}).10.7554/eLife.06253.008Figure 3.OXM treatment induces *Per1/2* expression in organotypic liver slices.(**A**--**C**) WT liver slices were treated with OXM (grey) or vehicle (PBS; black) at 180° and analyzed for clock gene expression of *Per1* (**A**; factor treatment F(1, 40) = 0.785; time F(3, 40) = 34.95; interaction F(3, 40) = 16.33), *Per2* (**B**; factor treatment F(1, 40) = 24.02; time F(3, 40) = 29.4; interaction F(3, 40) = 38.38), and *Bmal1* (**C**; factor treatment F(1, 40) = 0.108; time F(3, 40) = 17.39; interaction F(3, 40) = 3.607) by qPCR. (**D**--**F**) WT liver slices were treated with OXM (grey) or PBS (black) at 360° and analyzed for expression of *Per1* (**D**; factor treatment F(1, 40) = 1.179; time F(3, 40) = 36.33; interaction F(3, 40) = 1.349), *Per2* (**E**; factor treatment F(1, 40) = 5.757; time F(3, 40) = 13.57; interaction F(3, 40) = 1.135), and *Bmal1* (**F**; factor treatment F(1, 40) = 4.112; time F(3, 40) = 8.788; interaction F(3, 40) = 0.491) by qPCR. (**G** and **H**) OXM-induced *Per1/2* expression is retained in *Glp1r*^−/−^ liver slices. *Per1*: factor treatment F(1, 42) = 8.48; time F(2, 42) = 10.95; interaction F(2, 42) = 0.525. *Per2*: factor treatment F(1, 42) = 10.5; time F(2, 42) = 3.662; interaction F(2, 42) = 5.845. *Glp1r*^*−/−*^ liver slices were treated as described for WT above. Data are presented as mean ± S.E.M. (n = 6 for WT and 8 for *Glp1r*^*−/−*^). Two-way ANOVA with Bonferroni post-test: \*\*p \< 0.01; \*\*\*p \< 0.001.**DOI:** [http://dx.doi.org/10.7554/eLife.06253.008](10.7554/eLife.06253.008)

OXM resets the liver clock in vivo {#s2-3}
----------------------------------

To test if the effect of OXM on liver clock gene activity is preserved in vivo, we analyzed hepatic *Per1/2* transcription after OXM treatment in wild-type mice. Analogous to what we observed in slices, robust *Per1* and *Per2* induction was observed after *i.v.* injection of OXM at *Zeitgeber* time (ZT) 3 ([Figure 4A](#fig4){ref-type="fig"}). When animals were treated with OXM at the opposite phase of the LD cycle (ZT15)---a time when nocturnal mice usually eat and, thus, no food-mediated clock shifts would be expected---no induction of *Per* gene expression was observed ([Figure 4B](#fig4){ref-type="fig"}). Of note, in situ hybridization (ISH) showed no acute effect of OXM treatment on *Per* expression in the SCN at ZT3 ([Figure 4C](#fig4){ref-type="fig"}), indicating that OXM acts primarily on the liver clock and in line with the observed phase stability of the SCN clock under time-restricted feeding conditions ([@bib14]).10.7554/eLife.06253.009Figure 4.OXM treatment induces *Per1/2* expression and resets the liver circadian clock in vivo.(**A** and **B**) Hepatic *Per* gene expression after OXM (grey) or vehicle (PBS; black) *i.v*. injection at ZT3 (**A**) and ZT15 (**B**). ZT3: *Per1*: factor treatment F(1, 24) = 5.695; time F(2, 24) = 34.74; interaction F(2, 24) = 4.965; *Per2*: factor treatment F(1, 24) = 64.84; time F(2, 24) = 9.381; interaction F(2, 24) = 6.915. ZT15: *Per1*: factor treatment F(1, 12) = 1.096; time F(2, 12) = 0.005; interaction F(2, 12) = 1.367; *Per2*: factor treatment F(1, 24) = 0.255; time F(2, 24) = 0.001; interaction F(2, 24) = 1.172. (**C**) Suprachiasmatic nucleus (SCN) signal after in situ hybridization (ISH) of brain sections with ^35^S-labelled antisense probes for *Per1/2* 30 min after OXM/PBS treatment at ZT3 in the same animals used in (**A**). Left panel: representative autoradiograph scans containing the SCN; right panel: quantification of the ISH. (**D**) Resetting of *Per2* and *Dbp* rhythms in livers of wild-type mice after an *i.p*. injection of either OXM (grey) or vehicle (PBS; black) after 12-hr darkness; *Per2*: factor treatment F(1, 24) = 5.531; time F(5, 24) = 46.37; interaction F(5, 24) = 18.71. *Dbp*: factor treatment F(1, 24) = 0.094; time F(5, 24) = 119.2; interaction F(5, 24) = 38.58. All data are presented as mean ± S.E.M. (n = 3--5). **A**, **B**, and **D**: two-way ANOVA with Bonferroni post-test: \*p \< 0.05, \*\*p \< 0.01; \*\*\*p \< 0.001; **C**: Mann--Whitney test.**DOI:** [http://dx.doi.org/10.7554/eLife.06253.009](10.7554/eLife.06253.009)

To assess OXM effects on liver clock phase, we next treated wild-type mice with either PBS or OXM at the beginning of their rest phase on the first day in constant darkness (DD) and under fasting conditions, thus excluding potential confounding effects of light exposure or food intake. *Per2* and *Dbp* expression were determined from liver cDNA preparations at different time points using qPCR. We detected phase delays of *Per2* and *Dbp* mRNA rhythms in livers of OXM-treated mice relative to those in PBS-injected control animals ([Figure 4D](#fig4){ref-type="fig"}), in line with the phase-delaying effects of OXM administration in slices at this time ([Figure 1G](#fig1){ref-type="fig"}). In addition, *Per2*, but not *Dbp*, rhythms appeared dampened after OXM injection.

Tissue clocks regulate local physiology via coordination of transcriptional programs. To test if OXM treatment would impinge on hepatic energy metabolism, we analyzed the expression of important metabolic transcripts after OXM treatment. Similar to what we observed for clock gene activity, transcript profiles of genes involved in liver carbohydrate metabolism were found either phase delayed (*Foxo1* and *Pdk4*; [Figure 5A,B](#fig5){ref-type="fig"}) and/or dampened (*Foxo1* and *Pklr*; [Figure 5A,C](#fig5){ref-type="fig"}). Of note *Pepck*, which was previously described as a clock output gene in liver ([@bib27]) was not rhythmic under these conditions, and OXM had no further effect on *Pepck* mRNA levels ([Figure 5D](#fig5){ref-type="fig"}). Expression levels of the glucose transporter *Slc2a2* (*Glut2*) and the pyruvate transporter *Slc16a7* were also dampened or phase-delayed, respectively ([Figure 5E,F](#fig5){ref-type="fig"}).10.7554/eLife.06253.010Figure 5.OXM treatment modulates diurnal expression profile of hepatic genes involved in liver carbohydrate metabolism.(**A**--**F**) Relative gene expression of *Foxo1* (**A**; factor treatment F(1, 24) = 0.001, time F(5, 24) = 5.547, interaction F(5, 24) = 11.13), *Pdk4* (**B**; factor treatment F(1, 24) = 0.197, time F(5, 24) = 3.35, interaction F(5, 24) = 3.247), *Pklr* (**C**; factor treatment F(1, 24) = 11.63, time F(5, 24) = 5.61, interaction F(5, 24) = 3.61), *Pepck* (**D**; factor treatment F(1, 24) = 0.574, time F(5, 24) = 2.043, interaction F(5, 24) = 0.299), the glucose transporter *Slc2a2* (**E**; factor treatment F(1, 24) = 2.582, time F(5, 24) = 15.98, interaction F(5, 24) = 2.642) and the pyruvate transporter *Slc16a7* (**F**; factor treatment F(1, 24) = 1.539, time F(5, 24) = 7.472, interaction F(5, 24) = 6.586) after *i.p*. administration of either OXM (grey) or vehicle (PBS; black) after 12 hr in darkness. Data are presented as mean ± S.E.M. (n = 4). Two-way ANOVA with Bonferroni post-test: \*p \< 0.05, \*\*p \< 0.01; \*\*\*p \< 0.001.**DOI:** [http://dx.doi.org/10.7554/eLife.06253.010](10.7554/eLife.06253.010)

In summary, our data so far show that OXM treatment resets liver circadian mRNA rhythms in a phase- and dose-dependent manner, indicating that it may be involved in food-induced resetting of the liver circadian clock and metabolic machinery.

Food intake-mediated OXM induction and liver clock resetting {#s2-4}
------------------------------------------------------------

In humans, OXM levels in the blood rise in response to food intake ([@bib28]). To test whether this effect is conserved in mice, we determined diurnal plasma oxyntomodulin-like immunoreactivity (OLI) profiles in mice with ad libitum food access and in fasted animals. In fed mice, OLI levels were elevated during the active dark phase, while under fasting conditions OLI concentrations were constant and consistently low ([Figure 6A](#fig6){ref-type="fig"}). In line with this, non-rhythmic *Gcg* mRNA expression in the gut was observed under fasting conditions (data not shown). These data suggest a link between food intake and OXM secretion. To test this more directly, we used a 12-hr fasting-refeeding paradigm. Mean fasting OLI levels in the early morning (ZT1) were ∼3.5 ng/ml, but showed high inter-individual variation ([Figure 6B](#fig6){ref-type="fig"}). Upon food intake, a rapid increase (relative to individual fasting levels) was observed after 20 min. This effect persisted for more than 1 hr before returning to baseline levels ([Figure 6C](#fig6){ref-type="fig"}). Of note, OLI induction after OXM injections were about twofold--threefold higher than what was observed after refeeding ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). To test if postprandial OLI induction is sufficient to affect liver clock gene expression, we analyzed *Per1*/*2* mRNA levels in livers of wild-type mice after fasting-refeeding. Parallel to the rise in plasma OLI, we observed a transient postprandial increase of hepatic *Per1* expression. *Per2* expression showed a delayed, but a more persistent induction ([Figure 6D](#fig6){ref-type="fig"}). Food-mediated *Per* activation was partly inhibited by treatment with purified *anti*-OXM IgG to neutralize the effects of endogenous OXM in wild-type ([Figure 6E](#fig6){ref-type="fig"}) and in *Glp1r*^*−/−*^ mice ([Figure 6F](#fig6){ref-type="fig"}). Importantly, the effects of refeeding on insulin, GLP-1, and GCG plasma levels were not affected by treatment with *anti*-OXM IgG, suggesting that these peptides are not involved in the activation of food-induced hepatic *Per* expression ([Figure 6G--I](#fig6){ref-type="fig"}).10.7554/eLife.06253.011Figure 6.Endogenous OXM signaling regulates food intake-mediated resetting of the liver circadian clock.(**A**) Plasma oxyntomodulin-like immunoreactivity (OLI) diurnal profiles under ad libitum food and fasting conditions. Data are presented as mean ± S.E.M (n = 6); factor time F(5, 60) = 0.628, feeding condition F(1, 60) = 15.37, interaction F(5, 60) = 0.638. Grey shading indicates the dark phase. (**B**) OLI levels show high individual variations in mice after 12 hr of food deprivation (ZT13-1). (**C**) Plasma OLI (normalized to individual fasting levels) after refeeding (grey line) or under continuous starving (black line); factor time F(3, 21) = 3.544, feeding condition F(1, 21) = 15.82, interaction F(3, 21) = 4.717. (**D**) Liver *Per1/2* induction following fasting-refeeding determined by qPCR; *Per1*: factor time F(3, 25) = 0.454, feeding condition F(1, 25) = 1.376, interaction F(3, 25) = 4.453; *Per2*: factor time F(3, 25) = 6.938, feeding condition F(1, 25) = 38.48, interaction F(3, 25) = 3.767. (**E**) WT and (**F**) *Glp1r*^*−/−*^ liver *Per1/2* expression after fasting-refeeding with control IgG injection (grey) or OXM immuno-neutralization by *anti*-OXM IgG (aOXM) injection at ZT0; WT: *Per1*: F(2, 12) = 71.76, *Per2*: F(2, 12) = 47.41; *Glp1r*^*−/−*^: *Per1* F(2, 12) = 11.51, *Per2*: F(2, 12) = 5.585. (**G**--**I**) Treatment with *anti*-OXM IgG does not affect postprandial regulation of insulin, GLP-1, and GCG. Plasma levels of insulin (**G**; F(2, 12) = 17.44), GLP-1 (**H**; F(2, 12) = 5.563), and GCG (**I**; F(2, 12) = 7.128) after fasting-refeeding with control IgG injection (grey) or OXM immuno-neutralization by *anti*-OXM IgG (aOXM) treatment at ZT0. One- (**E**--**I**) or two-way ANOVA (**A**, **C**, **D**) with Bonferroni post-test: \*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001 against fasted; \#\#p \< 0.01; \#\#\#p \< 0.001 against IgG. Data are presented as mean ± S.E.M (n = 5). (**J** and **K**) Liver PER2::LUC rhythms after fasting-refeeding with control IgG or αOXM administration. (**J**) Representative luminescence traces. (**K**) Comparison of phases (second peak in culture) after refeeding and/or *anti*-OXM treatment (Data are presented as mean ± S.E.M (n = 4 mice per condition, an average of 3 slice preparations of each mouse were used); two-way ANOVA with Bonferroni post-test: \*p \< 0.05 against fasted; factor treatment F(1, 12) = 5.127, feeding condition F(1, 12) = 13.02, interaction F(1, 12) = 5.044).**DOI:** [http://dx.doi.org/10.7554/eLife.06253.011](10.7554/eLife.06253.011)10.7554/eLife.06253.012Figure 6---source data 1.Primer sequences for PCR reactions.**DOI:** [http://dx.doi.org/10.7554/eLife.06253.012](10.7554/eLife.06253.012)10.7554/eLife.06253.013Figure 6---figure supplement 1.Time course of OLI plasma levels after OXM injection.Time course of OLI appearance in plasma following *i.v.* (4 μg) or *i.p.* (25 μg) injections of OXM. OLI plasma level changes are expressed relative to starving levels (0 min) for each individual. Data are presented as mean ± SEM (n = 5). 2-way ANOVA with Bonferroni post-test: \*\*\*p \< 0.001; factor treatment F(2, 48) = 9.014, feeding condition F(3, 48) = 4.95, interaction F(6, 48) = 5.698.**DOI:** [http://dx.doi.org/10.7554/eLife.06253.013](10.7554/eLife.06253.013)

We next tested if OXM signaling regulates food-mediated phase resetting of the liver clock using *Per2::LUC* slice preparations. *Per2::LUC* mice were starved overnight (ZT12-24/0) and treated with either IgG or *anti*-OXM antibodies prior to re-feeding or extended starving. Animals were sacrificed at ZT4 and liver slices were prepared to determine luciferase rhythm phases. After a 12-hr fast, food intake caused a significant phase delay of PER2::LUC activity in liver slices and this effect was attenuated by OXM neutralization ([Figure 6J,K](#fig6){ref-type="fig"}). No effect on PER2::LUC phase was seen after *anti*-OXM treatment alone ([Figure 6K](#fig6){ref-type="fig"}).

Together, these data suggest that elevated OXM levels in response to food intake affect hepatic clock gene expression. Neutralization of endogenous OXM signaling inhibits food-induced clock gene induction and rhythm shifts, suggesting that OXM may act as a metabolic synchronizer of hepatic clocks.

Discussion {#s3}
==========

Food intake resets circadian clocks in peripheral tissues. In consequence, eating during the normal rest phase leads to a state of internal circadian desynchrony which has been suggested to underlie metabolic deregulation under shiftwork conditions ([@bib48]; [@bib39]; [@bib9]). Different mechanisms of food-related circadian synchronization have been proposed, including blood glucose-responsive peptide hormones ([@bib15]; [@bib45]; [@bib12]; [@bib44]). However, food entrainment does not exclusively depend on glucose ([@bib24]), and the molecular mechanisms underlying food entrainment of peripheral tissues remain poorly characterized ([@bib15]). Here, we identified the incretin peptide OXM as a potential direct link between food intake in the gut and resetting of hepatic clock and metabolic gene transcription.

Using an organotypic slice culture system, we found that OXM---and, as was shown recently, GCG ([@bib44])---treatment can reset PER2::LUC circadian reporter activity rhythm in a dose- and phase-dependent manner ([Figure 1](#fig1){ref-type="fig"}). Consistently, peripheral OXM injections in mice reset clock gene rhythms, as well as genes involved in hepatic carbohydrate regulation, thus impinging on hepatic energy metabolism ([Figures 4, 5](#fig4 fig5){ref-type="fig"}). In contrast, no significant effect of OXM treatment was observed at the level of the SCN pacemaker ([Figure 4](#fig4){ref-type="fig"}). In mice, food intake during day (i.e., the normal rest time) uncouples the liver clock from that in the SCN ([@bib27]), leading to a state of internal circadian desynchrony that is associated with elevated body weight and other metabolic impairments ([@bib5]; [@bib22]). In the liver, around 10% of the transcriptome is under circadian regulation including many genes involved in energy metabolism ([@bib1]; [@bib33]). Genetic ablation of the liver clock abolishes the circadian rhythms of several glucose regulatory genes and results in a perturbed diurnal profile of blood glucose ([@bib26]; [@bib27]).

Our experiments suggest that OXM signaling involves activation of GCGR ([Figure 2](#fig2){ref-type="fig"}). This is puzzling given that OXM displays a much greater capacity for clock gene induction in liver slices than GCG itself, despite having a lower binding affinity for GCGR ([@bib29]). While we cannot conclusively answer this question at the moment, there are two scenarios that might explain our observations. First, GCGR may not be the only receptor involved in OXM-mediated clock resetting. While our data suggest that GLP1R does not play a role in this context ([Figures 2, 3](#fig2 fig3){ref-type="fig"}), an additional OXM receptor has been suggested ([@bib6]; [@bib44]), the activation of which may interact with GCGR downstream signaling. Second, an additional signal may be involved that acts synergistically with OXM to activate hepatic *Per* transcription. One such candidate could be insulin, which is similarly elevated after food intake and has previously been suggested to affect liver clock rhythms ([@bib50]; [@bib12]; [@bib44]). In response to food intake OXM levels go up, while GCG plasma concentrations are reduced ([Figure 6](#fig6){ref-type="fig"}), suggesting that postprandial GCGR activation does not depend on GCG itself. Interestingly, GCG/GCGR signaling has recently been implicated in the regulation of hepatic *Bmal1* expression in response to prolonged starvation ([@bib44]). Sun et al. show that fasting-induced GCG signaling activates *Bmal1* transcription via CREB/CRTC2 during the night. As we did not observe any acute effects of OXM treatment on *Bmal1* transcription ([Figure 3](#fig3){ref-type="fig"}), these data suggest that GCGR signaling may have different clock targets depending on the time of activation. GCGR activation is known to induce protein kinase A-mediated nuclear translocation and DNA-binding of phosphorylated CREB on target genes ([@bib20]; [@bib13]). In line with this, we show OXM-induced binding of CREB to *Per1* promoter *CRE* motifs and induction of *Per* clock gene expression ([Figures 2--4](#fig2 fig3 fig4){ref-type="fig"}). Similar phase-dependencies were observed for *Per* induction as were seen for clock shifting (compare [Figures 1, 3, 4](#fig1 fig3 fig4){ref-type="fig"}). For various tissues---including the SCN---it has been shown that resetting of the circadian clock involves acute up-regulation of *Per1* and *Per2* ([@bib17]; [@bib31]). *Per* induction was observed after DEX treatment or serum shock in fibroblast and hepatoma cells ([@bib7], [@bib8]). Light pulses given during the dark phase induce CREB activation and *Per* expression in the SCN ([@bib2]; [@bib51]). In line with this, we showed *Per1* and *Per2* induction after OXM treatment. Of note, *Per* induction in liver slices was weaker than in vivo, suggesting that additional mechanisms may amplify OXM effects in intact animals. Along the same line, OXM-mediated *Per* induction in vivo appeared to be slightly faster than in slices ([Figures 3, 4](#fig3 fig4){ref-type="fig"}). Importantly, peripheral treatment with OXM also altered the diurnal expression rhythms of genes involved in regulating liver carbohydrate metabolism which may underline the metabolic effects of daytime feeding in rodents ([Figure 5](#fig5){ref-type="fig"}). Similar to the OXM effects on clock gene expression ([Figures 3, 4](#fig3 fig4){ref-type="fig"}), refeeding acutely induces hepatic *Per1/2* expression, which has been proposed as an integral part of the food-driven clock-resetting mechanism ([@bib34]; [@bib45]). In our study, we demonstrated that food intake after overnight fasting stimulated OXM secretion and led to hepatic up-regulation of *Per* expression, which was blocked by OXM neutralization in the circulation. Accordingly, liver slice cultures from re-fed *Per2::LUC* reporter mice showed food-dependent phase delays and these effects were attenuated by OXM neutralization ([Figure 6](#fig6){ref-type="fig"}). OXM neutralization does not completely inhibit the effects of refeeding on *Per* induction and liver clock resetting. This might be due to incomplete neutralization of OXM or the contribution of other food-induced factors as discussed above. Of note, while our data do not provide evidence for a direct involvement of GLP-1(R), it has been suggested that postprandial GLP-1 signaling may indirectly affect liver clock phase ([@bib36]).

Our data indicate an involvement of OXM signaling in food-driven resetting of the liver circadian clock. Similar to what was previously reported in humans ([@bib32]), we detected elevated OLI levels in fed as compared to starved mice and in response to acute food intake ([Figure 6](#fig6){ref-type="fig"}). The diurnal variability of OLI under ad libitum feeding conditions was moderate, but fasting resulted in an approximate 20% reduction of diurnal OLI secretion. Together this indicates that small meals as consumed during the inactive phase affect OXM secretion, but that substantial food intake is necessary to acutely increase OXM secretion to an extent sufficient to affect the liver clock. Of note, interpretation of plasma OXM blood levels is difficult as many OXM assays exhibit some degree of cross-reactivity with GCG and the closely related glicentin. Glicentin differs from OXM only by a 32-amino acid N-terminal extension (IP-1; [Figure 1](#fig1){ref-type="fig"}) and is released from the gut after food intake at approximately similar levels ([@bib10]; [@bib47]), thus we cannot exclude the possibility that glicentin may exhibit actions that overlap with those described for OXM.

In summary, we show that food intake induces OLI blood levels and hepatic clock resetting in mice. OXM treatment mimics food-mediated clock resetting in slices and in vivo in a time of day-dependent manner. Food is a major regulator of hepatic transcriptome rhythms ([@bib48]). A role for metabolic hormones, for example, insulin, GCG, or glucocorticoids, in the regulation of peripheral clocks has been suggested ([@bib8]; [@bib45]; [@bib44]). However, the mechanisms of food-related synchronization of peripheral clocks and their uncoupling from the SCN under time-restricted food intake rhythms are still poorly understood. Our data suggest that OXM---most likely in concert with other gut- and pancreas-derived hunger- or satiety-signaling peptides---is involved in the detrimental effects of mistimed food intake on metabolic homeostasis ([@bib5]; [@bib3]; [@bib22]). While interfering with insulin signaling may be clinically problematic because of its potential deleterious effects on glycemia, chronotherapeutic targeting of peripheral incretin signaling may provide an alternative therapeutic strategy against metabolic disorders arising from circadian strain as observed in shift workers or during jetlag.

Materials and methods {#s4}
=====================

Animal strains {#s4-1}
--------------

All animal experiments were ethically assessed and licensed by the Office of Consumer Protection and Food Safety of the State of Lower Saxony and in accordance with the German Law of Animal Welfare (license nos. V312-7224.122-4 and 33.12-42502-04-12/0893). For all experiments adult wild-type mice male C57BL/6J (8--24 weeks old) were used. If not stated otherwise, mice were provided with food and water ad libitum. To investigate the effect of OXM on gene expression by qPCR or ISH, mice were peripherally treated with OXM (*i.v.* 4 µg/mouse; *i.p.* 25 µg/mouse) or vehicle (PBS) at ZT3, ZT15, or 12 hr after light-off. For luminescence measurements adult heterozygous males *Per2::LUC* ([@bib53]) and *Per2::LUC* x *Glp1r*^*−/−*^ were used. *Glp1r*^*−/−*^ mice were maintained on a C57B/6J background ([@bib40]). All mice were exposed to a 12-hr: 12-hr light--dark cycle with 100 lux in the light phase (LD12:12). Animals were sacrificed at indicated time points by cervical dislocation. Animals euthanized during the dark phase were handled under red light and eyes were removed before dissection. All tissue samples were collected and immediately snap-frozen on dry ice or liquid nitrogen. For long-term storage tissues were kept at −80°C.

Refeeding experiments {#s4-2}
---------------------

In order to test *Per* induction and phase shifts after refeeding, mice were fasted for one night (13 hr, or from ZT12---ZT1) and either food deprived until decapitation or refed at ZT1. The refed mice received either *anti*-OXM rabbit IgG (*i.p.* 50 µg/mouse; T-4800; Bachem, Bubendorf, Switzerland) or control IgG from unimmunized rabbit serum (I5006; Sigma-Aldrich, Seelze, Germany) at ZT1 when food was returned.

Liver slice cultures and peptide treatments {#s4-3}
-------------------------------------------

Luminescence was measured from cultured liver slices of heterozygous *Per2::LUC* mice as described previously ([@bib53]) modified to include the use of culture plate inserts (Millipore, Billerica, MA). Briefly, the median lobe of the liver was isolated and 300-µm slices were prepared using a vibratome (Campden Instruments, Loughborough, UK). The slices were immediately placed onto a culture plate insert in 35-mm petri dishes filled with 1-ml culture medium (D-MEM with high glucose, w/o L-glutamine and phenol red; Life Technologies, Darmstadt, Germany) supplemented with 3 mM sodium carbonate (Sigma--Aldrich), 10 mM HEPES buffer, 2 mM L-glutamine, 2% B-27 supplement, 25 U/ml penicillin/streptomycin and 0.1 mM D-luciferin (all Life Technologies). Luminescence was measured in a luminometer (Actimetrics, Evanston, IL) at 32.5°C with 5% CO~2~. Analyses were performed using the LumiCycle analysis (Actimetrics) and Prism software packages (GraphPad, La Jolla, CA). PER2::LUC activity in slices closely follows a sine wave shape. The intersection of the ascending cross-section of the sine wave with the x-axis was defined as 0°/360°, the peak as 90°. Degrees at the time point of treatment were calculated as follows: *T*~*p*~ *\[°\] = ((T*~*p*~ *\[hsm\] − P*~*bt*~ *\[hsm\])*: *P*~*bt*~*)* × *360 + 90* with T~p~ = treatment phase; ° = degree; hsm = hours after start of measurement; P~bt~ = peak before treatment. If the result was \>360°, the value was subtracted by 360. Raw data were baseline subtracted with running averages of 24 hr. Peaks were defined as middle time point between two troughs of the sine wave. Period was determined as the time between peaks averaged over 2--3 consecutive cycles. For the duration of treatment, samples were maintained at 32.5°C to avoid resetting of clock gene expression rhythms due to temperature changes. Phase shifts were determined by comparing extrapolated peak times from sine wave fits before and after treatment. Unless otherwise stated, peptides used for experiments were dissolved in culture medium and administered at a final concentration of 450 pM.

Quantitative real-time (qPCR) {#s4-4}
-----------------------------

Quantitative real-time PCR (qPCR) was performed with a CFX96 thermocycler system (Bio-Rad, Munich, Germany) with iQ-SYBR Green SuperMix (Bio-Rad). Relative quantification of expression levels by a modified ΔΔCT calculation was performed as described ([@bib37]). *ß-Actin* was used as a reference gene. Statistical analyses were performed using GraphPad Prism software. Circadian profiles of clock gene expression were normalized against the average values over all time points. Induction analyses were normalized against untreated conditions (0 min). PCR primer sequences are listed in [Figure 6---source data 1](#SD2-data){ref-type="supplementary-material"}.

ISH {#s4-5}
---

The *Per1* probe corresponds to nucleotides 1 to 619 (GenBank accession number AF022992) and *Per2* corresponds to nucleotides 229 to 768 of GenBank AF036893. PCR products had been cloned into *pCR II TOPO* vector using TOPO TA Cloning Kit (Life Technologies) ([@bib35]). Linearization of vectors for in vitro transcription was done with EcoRI. ^35^S-UTP (PerkinElmer, Waltham, MA) labeled RNA probes were prepared using RNA Transcription Kit (Maxi Script Labeling Kit, Life Technologies) with T7 or T3 RNA polymerases according to the manufacturer\'s protocol. 10-µm cryosections were cut using a Leica CM3050 cryostat. Cryosections were fixed in 4% paraformaldehyde, acetylated in acetic anhydride and dehydrated with ethanol. Hybridization was performed over night at 55--58°C. Autoradiographs were analyzed by densitometry (Bio-Rad GS-800) using QuantityOne software (Bio-Rad). Three sections per brain were used and background values were calculated from adjacent tissue areas on the same slide for each section. Measurements from different animals/experiments were compared for statistical analysis using GraphPad Prism (GraphPad).

ChIP {#s4-6}
----

Liver slices were homogenized and immediately cross linked with 1% formaldehyde. Chromatin was sonicated for 15-s on/20-s off cycles for 22 min using a Bioruptor sonicator (Diagenode, Denville, NJ). Samples were incubated overnight at 4°C with CREB antibody (ab31387, Abcam, Cambridge, UK). After clearing, samples were incubated with A/G agarose beads (Thermo Scientific, Braunschweig, Germany) for 1 hr at 4°C followed by repetitive washings. After boiling for 10 min in 10% Chelex (Bio-Rad) with Proteinase K (150 mg/ml), samples were spun down and DNA-containing supernatant was collected for PCR. qPCR was performed as described above, and values were normalized to percentage of input. Primer sequences were: 5′-CAGCTGCCTCGCCCCGCCTC-3′/5′-CCCAAGCAGCCATTGCTCGC-3′ (Per1 CRE) and 5′-CCCCGCAGTCCTACGGTGCTG-3′/5′-AAGCCCCCAAACAACTGAAGGT-3′ (500 bp downstream sequence).

Hormone measurements {#s4-7}
--------------------

Blood collection for radioimmunoassay (RIA) was performed at ZT1 after 12 hr fast. Mice were allowed to recover for 3 days, then fasted again followed by treatments (with or without refeeding). Blood was collected from the tail vein at 0 min, 20 min, 60 min, and 120 min after treatment. Plasma concentrations of OLI were determined by RIA (Phoenix Pharmaceutics, Karlsruhe, DE) according to manufacturer\'s protocol modified to use a 50% reaction volume. GLP-1 (EZGLP-1T-36K, Millipore, Darmstadt, Germany), insulin (Catalog\# 90080, CrystalChem, Downers Grove, IL), and GCG plasma levels (EZGLU-30K, Millipore) were determined by ELISA according to the manufacturers\' protocols.

Statistics {#s4-8}
----------

Data were analyzed with GraphPad Prism (GraphPad). Mann--Whitney tests were used for simple comparisons. For dose responses one-way ANOVAs and for two-factor comparisons two-way ANOVAs with Bonferroni post-tests were used. A p-value of less than 0.05 was considered significant.
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eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see [review process](http://elifesciences.org/review-process)). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

Thank you for sending your work entitled "Oxyntomodulin regulates resetting of the liver circadian clock by food" for consideration at *eLife*. Your article has been favorably evaluated by Janet Rossant (Senior editor) and 3 reviewers, one of whom, Louis Ptacek, is a member of our Board of Reviewing Editors.

The Reviewing editor and the other reviewers discussed their comments before we reached this decision, and the Reviewing editor has assembled the following comments to help you prepare a revised submission.

The findings in this paper strongly point to a physiological role of OXM in the regulation of the liver circadian clock that arises following the ingestion of food. This study complements earlier work by other groups that examine how corticosterone or body temperature can synchronize clocks in peripheral tissues. OXM has not been implicated in this process and this study demonstrates a new role for this neuropeptide. Moreover, the findings also point to unusual receptor signaling mechanisms as underpinning the actions of OXM in the liver.

Minor comments:

1\) How do the doses of OXM used in this study compare to what is known regarding the physiological concentrations of OXM?

2\) Mice generally eat most during the lights-off phase, but will occasionally spontaneously eat small meals and water during the lights-on phase. Does this mean then that the release of a critical liver resetting concentration of OXM is only achieved when substantially more food is consumed during the day than is typical?

3\) Are the effects of OXM on Per2 in the liver always indicative of induction? There seems to be some variation from one experiment to another or possible alternative interpretations.

4\) A statement in the Methods on how the results were statistically analysed would be helpful, e.g. what statistics software package was used, significance levels used etc. Also, why not report F-values and Deg. of Freedom in the figure captions?

5\) What is known about the cycling of OXM transcript in the gut? Does this vary circadianly in the absence of food intake?

6\) It would be informative to include representative examples of bioluminescence rhythms from the liver slices, showing the phase shift effect of OXM. This would make it clearer to a reader not familiar with such experiments.
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Author response

1\) How do the doses of OXM used in this study compare to what is known regarding the physiological concentrations of OXM?

We have added a new supplemental figure ([Figure 6--figure supplement 1](#fig6s1){ref-type="fig"}) in which we measure blood OLI levels after i.v. and i.p. injection as used in this paper. When one compares these to the refeeding data ([Figure 6C](#fig6){ref-type="fig"}), it becomes clear that the OXM concentrations after injection are around 2-3 fold higher than after re-feeding. We added this information into the subsection of the Results headed "Food intake-mediated OXM induction and liver clock resetting".

2\) Mice generally eat most during the lights-off phase, but will occasionally spontaneously eat small meals and water during the lights-on phase. Does this mean then that the release of a critical liver resetting concentration of OXM is only achieved when substantially more food is consumed during the day than is typical?

We now include a new panel in [Figure 6](#fig6){ref-type="fig"} (revised [Figure 6A](#fig6){ref-type="fig"}) where we compare blood OLI levels between mice under ad libitum feeding conditions and fasted animals. Overall OLI levels are 20% higher in fed animals (p \< 0.001 for feeding condition in a 2-way ANOVA), and the difference is strongest during the lights-off phase. This suggests that even small meals as consumed during the light phase can affect OLI, but the overall variation is too high for this effect to reach significance at any single time point during the lights-on phase. We discuss this in the Discussion section.

*3) Are the effects of OXM on Per2 in the liver always indicative of induction? There seems to be some variation from one experiment to another or possible alternative interpretations*.

In our hands *Per2* induction was consistently observed after OXM treatment. However, without longitudinal measurements (e.g. by using in vivo PER2::LUC recordings as introduced by Saini et al. Genes Dev 2013 Jul 1;27(13):1526-36) occasional non-responders cannot be excluded.

*4) A statement in the Methods on how the results were statistically analysed would be helpful, e.g. what statistics software package was used*, *significance levels used etc. Also, why not report F-values and Deg. of Freedom in the figure captions?*

We have added this information (Methods section and in the figure captions).

5\) What is known about the cycling of OXM transcript in the gut? Does this vary circadianly in the absence of food intake?

We have measured *Gcg* mRNA rhythms (as the precursor mRNA of OXM) in the gut under fasting conditions (see [Author response image 1](#fig7){ref-type="fig"}) and blood OLI levels under ad libitum food and fasting conditions (revised [Figure 6A](#fig6){ref-type="fig"}). mRNA and peptide levels are non-rhythmic under fasting conditions, while under ad libitum feeding OLI is elevated during the dark phase when mice are active and eat most of their food. Since *Gcg* also gives rise to other peptides besides OXM, we believe that the mRNA data are not very informative for our story and, thus, only mention these data briefly in the main text (in the subsection headed "Food intake-mediated OXM induction and liver clock resetting")10.7554/eLife.06253.016Author response image 1.Circadian mRNA expression of *Gcg* and *Dbp* in the gut of fasted mice. Animals were released into constant darkness and samples were collected at 4 time points under fasting conditions on day 3. While *Dbp* shows a robust circadian rhythm, *Gcg* mRNA is expressed at comparable levels throughout the circadian cycle. Data are mean ± SEM (n = 4).**DOI:** [http://dx.doi.org/10.7554/eLife.06253.016](10.7554/eLife.06253.016)

*6) It would be informative to include representative examples of bioluminescence rhythms from the liver slices, showing the phase shift effect of OXM. This would make it clearer to a reader not familiar with such experiments*.

We have added representative bioluminescence traces to [Figure 1](#fig1){ref-type="fig"} to exemplify the data obtained from this type of resetting experiments.
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